© 2026 Sinochem Nanjing Corporation,
All Right Reserved
Enrofloxacin Base stands as a veterinary antibiotic, prized for its fluoroquinolone structure and broad-spectrum antibacterial activity. Developed first for livestock and poultry, this substance helps manage bacterial diseases that often threaten animal health and farm productivity. Chemically, Enrofloxacin Base is recognized by its molecular formula C19H22FN3O3 and offers strong potency by inhibiting bacterial DNA gyrase, which shuts down the internal processes of harmful bacteria. Over several years in animal healthcare work, I have seen just how critical swift, dependable antibiotics can be for ensuring food security. Farms large and small value this product not for any bells and whistles but for the clear difference it makes in animal recovery rates and disease prevention, impacting both animal welfare and economic stability for producers.
This chemical arrives as a solid, usually a white to light yellow crystalline powder. The feel between fingers recalls fineness similar to cornstarch, yet offers a density of about 1.48 g/cm³, which becomes important in packaging and dosing. Enrofloxacin Base does not display a strong odor. Its melting point hovers between 220°C and 224°C, key when technicians handle or blend this compound into injectable or oral solutions. Solubility marks another defining trait: it dissolves only sparingly in water, so most manufacturers process it further into soluble forms for veterinary use. Handling the base powder calls for attention to dust, as inhalation can pose hazards, a lesson driven home to many who have worked in compounding pharmacies and feed mills.
Enrofloxacin Base falls into the quinolone family, identified sharply by a bicyclic core carrying both a fluorine atom and a piperazine ring. These elements enhance its activity, pushing it far beyond the reach of older veterinary antibiotics. Its chemical structure contributes directly to its effectiveness, letting it penetrate bacterial cells and disrupt vital processes with clinical precision. This strong backbone allows for a wide killing range—gram-negative and gram-positive pathogens both fall in its scope. On the technical side, its molecular weight lands at 359.40 g/mol, and chemists routinely use mass spectrometry to confirm purity, which makes sense from a quality control standpoint, as impurities can ruin both shelf life and biological effect.
Enrofloxacin Base demonstrates versatility in form. Laboratories and supply firms distribute it as dense flakes, fine powder, or crystalline pearls, suitable for mixing in feed, dissolving for injectables, or further refinement. Solid forms ease transport and storage but bring risk of airborne particles, which those of us in pharmaceutical settings have stressed about during formulation. Liquid and ready-to-use solution versions also exist, though they typically involve the hydrochloride salt, not the pure base, due to improved water solubility. Each form aligns with tailored application: solid for bulk handling and premixes, solution for direct dosing. In storage, dry, shaded, and room-temperature spaces extend the shelf life, holding potency for longer cycles.
Suppliers focus on purity, targeting upwards of 98.0% content, with strict restrictions on heavy metal and related compound levels per regulatory frameworks. The chemical rolls out as raw material for animal medicine manufacturing—companies synthesize Enrofloxacin Base beginning with core aromatic and carboxylic acid building blocks, followed by fluorination and formation of the pivotal piperazine moiety. Many know the process draws from decades of organic chemistry innovation, blending safety and yield concerns. With established HS Code 2934999099, importing and exporting activities face clear checks, and authorities expect detailed records at every transaction, reflecting the compound’s significance and controlled status.
Enrofloxacin Base is not free from risk. Direct exposure irritates eyes, skin, and respiratory tract, sometimes triggering allergic symptoms among laboratory workers and factory staff. Inhalation of dust or accidental ingestion can bring on headaches, dizziness, or stomach upset. Risk management boils down to robust protective equipment—masks, gloves, dust control systems, and working in well-ventilated spaces. Any accidents prompt thorough washing with water and medical attention. Proper storage avoids fire risk, though the base is not Class I hazardous. Still, mishandling can lead to gradual build-up in work environments, so routine monitoring remains wise. Disposal must meet local environmental rules; wastewater and surplus powder often require specialized chemical neutralization, a step many overlook in day-to-day rush but that matters deeply for public health and sustainability.
Digging into properties and specifications of Enrofloxacin Base is not some dry technical exercise. Clinicians, pharmacists, and regulatory inspectors benefit from a clear grasp of physical structure, purity metrics, and handling risks. Proper product information makes real differences at the farm, factory, and treatment level. Vaccines alone do not shield animal populations from bacterial outbreaks—dependable, understood antibiotics like this one form a vital backstop. At the same time, keen awareness about safety and environmental stewardship tempers its advantages with necessary caution. Real health progress comes when production, safety, and careful stewardship of antibiotics move forward in lock-step.
